Illumina (ILMN)
(Delayed Data from NSDQ)
$130.14 USD
+2.41 (1.89%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $130.17 +0.03 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ILMN 130.14 +2.41(1.89%)
Will ILMN be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for ILMN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ILMN
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
ILMN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Should Invesco S&P 500 Equal Weight ETF (RSP) Be on Your Investing Radar?
Other News for ILMN
A Biobank for the Americas and a Genomics Lab Power Precision Health for All
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
Icahn’s All-In: 3 Stocks Billionaire Carl Icahn Is Betting Big On
Interesting ILMN Put And Call Options For May 17th
China stimulus positive for GE HealthCare, tool companies, says Evercore ISI